MY206262A - Macrocyclic tyrosine kinase inhibitor and uses thereof - Google Patents

Macrocyclic tyrosine kinase inhibitor and uses thereof

Info

Publication number
MY206262A
MY206262A MYPI2021002507A MYPI2021002507A MY206262A MY 206262 A MY206262 A MY 206262A MY PI2021002507 A MYPI2021002507 A MY PI2021002507A MY PI2021002507 A MYPI2021002507 A MY PI2021002507A MY 206262 A MY206262 A MY 206262A
Authority
MY
Malaysia
Prior art keywords
tyrosine kinase
kinase inhibitor
macrocyclic
relates
macrocyclic tyrosine
Prior art date
Application number
MYPI2021002507A
Inventor
Bin Liu
Original Assignee
Shandong Xuanzhu Pharma Co Ltd
Xuanzhu Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xuanzhu Pharma Co Ltd, Xuanzhu Biopharmaceutical Co Ltd filed Critical Shandong Xuanzhu Pharma Co Ltd
Publication of MY206262A publication Critical patent/MY206262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention belongs to the technical field of medicine, and relates to a macrocyclic tyrosine kinase inhibitor and the uses thereof. Specifically, the invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, a preparation method therefor, a pharmaceutical formulation or a pharmaceutical composition containing same, and medical uses thereof.
MYPI2021002507A 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof MY206262A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811328658 2018-11-09
CN201910091922 2019-01-30
PCT/CN2019/116459 WO2020094112A1 (en) 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
MY206262A true MY206262A (en) 2024-12-06

Family

ID=70611691

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021002507A MY206262A (en) 2018-11-09 2019-11-08 Macrocyclic tyrosine kinase inhibitor and uses thereof

Country Status (10)

Country Link
US (1) US12178807B2 (en)
EP (1) EP3878854A4 (en)
JP (1) JP7190036B2 (en)
KR (1) KR20210088675A (en)
CN (1) CN113166155A (en)
AU (1) AU2019375825B2 (en)
MY (1) MY206262A (en)
PH (1) PH12021551057A1 (en)
SG (1) SG11202104609SA (en)
WO (1) WO2020094112A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135938B (en) * 2020-01-19 2022-06-14 山东轩竹医药科技有限公司 Substituted macrocyclic tyrosine kinase inhibitors and uses thereof
CN113620974B (en) * 2020-05-08 2023-01-31 山东轩竹医药科技有限公司 Crystal form of macrocyclic tyrosine kinase inhibitor and preparation method thereof
CN111875620B (en) * 2020-09-28 2020-12-11 上海美迪西生物医药股份有限公司 Pyrazolopyrimidine macrocyclic derivative and application thereof
WO2023025141A1 (en) * 2021-08-23 2023-03-02 正大天晴药业集团股份有限公司 Use of macrocyclic compound containing amino in treatment of trk kinase-mediated tumors
CN113754657B (en) * 2021-09-22 2023-01-17 广州白云山医药集团股份有限公司白云山制药总厂 Crystal form of macrocyclic compound and its preparation method and application
WO2025194074A1 (en) * 2024-03-15 2025-09-18 Neuron23, Inc. Kinase modulators and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735420C (en) * 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
KR102015402B1 (en) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Macrocyclic compounds as trk kinase inhibitors
JP5997763B2 (en) * 2011-05-19 2016-09-28 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ Macrocyclic compounds as protein kinase inhibitors
PT2760453T (en) 2011-09-30 2016-08-02 Ipsen Pharma Sas Macrocyclic lrrk2 kinase inhibitors
AU2015209239C1 (en) * 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
JOP20190092A1 (en) * 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
US11098046B2 (en) 2017-11-10 2021-08-24 Angex Pharmaceutical, Inc. Macrocyclic compounds as TRK kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
PH12021551057A1 (en) 2021-12-06
US12178807B2 (en) 2024-12-31
SG11202104609SA (en) 2021-06-29
KR20210088675A (en) 2021-07-14
AU2019375825A1 (en) 2021-06-24
AU2019375825B2 (en) 2022-09-15
EP3878854A1 (en) 2021-09-15
US20210401814A1 (en) 2021-12-30
WO2020094112A1 (en) 2020-05-14
JP2022506802A (en) 2022-01-17
EP3878854A4 (en) 2022-08-10
JP7190036B2 (en) 2022-12-14
CN113166155A (en) 2021-07-23
AU2019375825A8 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
SA522433155B1 (en) Trisubstituted ring compounds
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021000887A (en) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
MY202371A (en) Hexone glucokinase inhibitor and use thereof
JOP20190229B1 (en) Compounds that inhibit mcl-1 protein
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
GEP20166484B (en) Protein kinase inhibitors
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
PH12022553024A1 (en) Inhibitors of nek7 kinase
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MY201382A (en) Pde9 inhibitor and use thereof
MX2021003655A (en) Indole macrocyclic derivative, preparation method therefor and application thereof in medicine.
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2021010106A (en) Inhibitors of integrated stress response pathway.
EA201391018A1 (en) PREPARATIONS OF IMMUNOSUPRESSANTS
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
SA519402103B1 (en) 1, 6- Naphthyridine as CDK4/6 Inhibitor
MX2023003576A (en) Compound as akt kinase inhibitor.
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
PH12021551232A1 (en) Haloallylamine compounds and application thereof
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof